Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery
PHASE2CompletedINTERVENTIONAL
Enrollment
50
Participants
Timeline
Start Date
August 11, 2020
Primary Completion Date
January 7, 2025
Study Completion Date
January 7, 2025
Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
DRUG
Nivolumab
3mg/kg
DRUG
Ipilimumab
1mg/kg
Trial Locations (1)
1066CX
NKI-AVL, Amsterdam
All Listed Sponsors
lead
The Netherlands Cancer Institute
OTHER
NCT04620200 - Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery | Biotech Hunter | Biotech Hunter